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Endocrinologic Disorders and Optic Pathway Gliomas in Children With
Neurofibromatosis Type 1
Marjon H. Cnossen, MD*‡; Esther N. Stam*; Linda C. M. G. Cooiman*; Huibert J. Simonsz, MD, PhD§;
Hans Stroink, MDi; Arnold P. Oranje, MD, PhD¶; Dicky J. J. Halley, PhD‡; Arja de Goede-Bolder, MD*;
Martinus F. Niermeijer, MD, PhD‡; and Sabine M. P. F. de Muinck Keizer-Schrama, MD, PhD#
ABSTRACT. Objective. To establish the prevalence of
endocrinologic disorders in children with neurofibroma-
tosis type 1 (NF1) and the relationship between these
disorders and cerebral abnormalities on magnetic reso-
nance imaging.
Design. A prospective follow-up study.
Setting. A multidisciplinary neurofibromatosis
clinic.
Patients. A total of 122 children diagnosed with NF1
according to diagnostic criteria set by the National Insti-
tutes of Health.
Results. Central precocious puberty (CPP) was diag-
nosed in 3 children and growth hormone deficiency
(GHD) in 3 children. Optic pathway gliomas were ob-
served in 15 children; in 9 of the 15 cases, the optic
chiasm was involved. Of the 3 children with CPP, only 1
showed a chiasma glioma on magnetic resonance imag-
ing. In 1 case with GHD, an optic chiasm glioma was
detected on neuroimaging. Two of the 9 children with an
optic chiasm glioma presented with CPP or GHD.
Conclusions. It has been suggested that CPP in chil-
dren with NF1 is found exclusively in the presence of a
chiasma glioma. We conclude that chiasma glioma may
not be obligatory in children with NF1 and CPP or GHD.
Moreover, we report a prevalence of GHD in children
with NF1 of 2.5%, which has not been established earlier.
Pediatrics 1997;100:667–670; neurofibromatosis type 1, en-
docrinologic disorder, central precocious puberty, growth
hormone deficiency, optic pathway glioma.
ABBREVIATIONS. NF1, neurofibromatosis type 1; NIH, National
Institutes of Health; CPP, central precocious puberty; GHD,
growth hormone deficiency; VEP, visual evoked potentials; CT,
computed tomography; MRI, magnetic resonance imaging; SD,
standard deviation; GH, growth hormone; LHRH, luteinizing hor-
mone-releasing hormone.
Neurofibromatosis type 1 (NF1) is an autoso-mal-dominant disorder affecting 1 in 3300individuals. Characteristic features are cafe´-
au-lait-colored spots, freckling in intertriginous re-
gions, neurofibromas, and Lisch nodules (iris hamar-
tomas). Diagnostic criteria have been established by
National Institutes of Health (NIH).1
Endocrine disorders have been reported in ;1% to
3% of all NF1 patients. In adults, pheochromocytoma
is the most common disorder, presenting in ;1% of
NF1 patients.2 In children with NF1, central preco-
cious puberty (CPP) is the most frequent endocrinop-
athy and is seen in 3% of NF1 patients compared
with .06% in the general pediatric population.2–4 Al-
though various case reports have been published, the
prevalence of growth hormone deficiency (GHD) in
children with NF1 is unknown and is assessed in this
paper.
Listernick et al5 reported that routine magnetic
resonance neuroimaging in 176 children with NF1
revealed optic pathway gliomas in 33 (19%). Almost
half of these gliomas were asymptomatic. In partic-
ular, gliomas of the optic chiasm have been reported
to cause endocrinologic disorders, especially CPP.6
In a prospective follow-up study in a multidisci-
plinary NF1 clinic, we analyzed the prevalence of
endocrinologic disorders in children and the rela-
tionship between these disorders and cerebral abnor-
malities on neuroimaging.
PATIENTS AND METHODS
Since 1985, a multidisciplinary NF1 team at Sophia Children’s
University Hospital in Rotterdam (including a pediatrician, der-
matologist, pediatric neurologist, ophthalmologist, and clinical
geneticist) has evaluated children suspected of having NF1 ac-
cording to NIH criteria. Besides periodic clinical evaluations, x-
rays of the cranium and the entire spine and a visual evoked
potential (VEP) are performed at presentation. Computed tomog-
raphy (CT) scanning and/or magnetic resonance imaging (MRI) is
initiated when indicated.
Before January 1995, 171 new cases were seen. NF1 was diag-
nosed in 122 children (58 girls, 64 boys). The average follow-up
period in the NF1-affected group was 4.4 years (standard devia-
tion [SD] 5 4.1). The mean age of these children at last examina-
tion date was 9.9 years (SD 5 5.3). Still at risk for CPP were 16 of
58 (28%) girls who were ,8 years of age and 25 of 64 (39%) boys
who were ,9 years of age at last examination date. Of the remain-
ing 49 children, 17 remained suspect for NF1, having only one
diagnostic criterion, other than a positive family history. In 32
children, the diagnosis of NF1 was rejected.
CPP was defined as the appearance of secondary sexual char-
acteristics before the age of 8 years in girls and 9 years in boys.
Secondary sexual characteristics included breast development of
at least Tanner stage B2 in girls and genital development of at least
Tanner stage G2 and a testicular volume of $4 mL in boys.7 In
addition, increased growth velocity, accelerated bone maturation,
and pubertal responses of plasma luteinizing hormone (.10
mU/L) during a standard luteinizing hormone-releasing hormone
(LHRH) stimulation test were present in all cases.8,9 Pituitary
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gonadotropin response to LHRH was obtained after intravenous
injection of 100 mg of LHRH. Subsequently, serum samples were
taken at 0, 30, and 60 minutes after injection.10
The diagnosis of GHD was based on a decreased height veloc-
ity over a period of at least 6 months or a decrease in height SD
score of .0.25/year.11 In addition, maximum plasma growth hor-
mone (GH) peaks remained below 20 mU/L in at least two stan-
dard pharmacologic provocation tests (clonidine, arginine). After
administration of 0.15 mg/m2 clonidine orally or 0.5 g/kg body
weight of arginine solution intravenously in 30 minutes, GH
plasma values were measured at 0, 30, 60, 90, 120, and 150 minutes
for the clonidine test, and at 0, 15, 30, 75, 90, and 120 minutes for
the arginine test. Plasma GH was determined by a specific radio-
immunoassay, using polyclonal antibodies after acid chromatog-
raphy.12 Prepubertal girls were estrogen-primed from the age of 8
years and prepubertal boys from the age of 9 years. A plasma
insulin-like growth factor 1 value of 2 SDs below the reference
values for age supported a diagnosis of GHD.12 Other causes of
decreased growth velocity were excluded.
Thyroid hormones were evaluated in all patients suspected of
having an endocrinologic abnormality; no abnormalities were de-
tected. Bone ages were analyzed according to Greulich and Pyle.12a
When bone age and chronologic age differed by .1 year, bone age
was considered divergent.
In our population, CT and MRI of the brain were performed
only on indication. Indications included endocrinologic disorders;
ophthalmologic abnormalities such as optic atrophy, a relative
afferent pupillary defect, an abnormal Ishihara color vision test, or
an abnormal VEP; mental retardation; and various other neuro-
logic abnormalities. In all patients suspected of having an optic
pathway glioma, a special protocol for the detection of these
gliomas was used.13 All patients with an endocrinologic disorder
were evaluated by MRI.
CPP patients were treated with the LHRH analogue Triptore-
line (Ferring, Hoofddorp, the Netherlands), a depot preparation,
once every 4 weeks intramuscularly. In GHD patients, treatment
was initiated with recombinant human GH.
Children who developed endocrinologic abnormalities second-
ary to cranial irradiation for a progressive optic pathway glioma
or malignancy were excluded from this study.
The study protocol was approved by the medical ethics com-
mittee of the Medical Faculty and the University Hospital Sophia/
Dijkzigt.
Data were analyzed using Dbase IV (Ashton-Tate, Amsterdam,
the Netherlands) and SPSS (Statistical Products and Services Inc,
Chicago, IL).
RESULTS
Endocrinologic disorders were diagnosed in 6 of
the 122 children (5.0%; 95% CI: 0.3%–9.7%), children
with definite NF1. All patients were boys. CPP was
diagnosed in 3 (2.5%) of the 122 children (Table 1).
Mean age at diagnosis was 7.3 years. GHD was de-
tected in 3 (2.5%) of the 122 children (Table 1). The
mean age at diagnosis was 9 years. In 5 of the 6
children, NF1 was also diagnosed in one of the par-
ents (3 mothers, 2 fathers).
In children diagnosed with CPP, a chiasma glioma
was seen on MRI in one child (patient A). Patients B
and C showed no optic pathway glioma on MRI and
had normal VEP, ophthalmologic, and neurologic
examinations (Table 1). Furthermore, a chiasma gli-
oma was observed in one child (patient D) diagnosed
with GHD (Table 1).
Although no routine neuroimaging studies were
performed, optic pathway gliomas were reported in
15 of 122 children with NF1 (12.3%; 95% CI: 6.5%–
18.1%); 6 of the 15 (40%) were located in the optic
nerve and in 9 of the 15 (60%), the optic chiasm was
involved. In 5 of the 15 (33.3%) children with an optic
pathway glioma, no ophthalmologic abnormalities
were observed after visual examinations and fundus-
copy; in 14 of the 15 (93.3%) VEPs were abnormal.
Endocrinologic disorders developed in 2 of the 9
children (22.2%; 95% CI: 10.2%–34.2%) with an optic
chiasm glioma; no endocrine disorders were seen in
children with an optic nerve glioma.
In total, 3 of 15 children (20%) were treated with
radiotherapy for a progressive optic pathway glioma
(mean age, 9.7 years); 2 of the 3 (66.6%) went on to
TABLE 1. Diagnosis of CPP and GHD in Children With NF1
CPP Patient
A B C
Optic pathway glioma* Optic nerve and chiasm 2 2
Ophthalmologic investigation† A N N
Sex m m m
Age at diagnosis NF1 (y) 6.2 7.5 4.8
Age at presentation of secondary sexual characteristics (y) 8.5 7.5 7.6
Increased growth velocity 1 1 1
Accelerated bone maturation 1 1 1
Maximal LH response to LHRH stimulation (100 mU/L, iv)
(prepubertal response , 10 mU/L)
18.7 53.0 14.1
GHD D E F
Optic pathway glioma* Optic chiasm 2 2
Ophthalmologic investigation† A A‡ N
Sex m m m
Age at diagnosis NF1 (y) 5.0 2.7 5.0
Age at diagnosis GHD (y) 8.6 11.3 7.0
Progressive deviation from growth curve 1 1 1
Delayed bone maturation 1 1 1
Maximum plasma GH value after provocation (mU/L)
Arginine test (normal: .20 mU/L) 11 8.5 13
Clonidine test (normal: .20 mU/L) 15 5.5 15
Plasma IGF-1 (,22 SD) 1 1 1
* All patients were screened by MRI, using a special protocol for detection of optic gliomas.
† Vision, fundoscopy, visual field examination.
‡ Hydrocephalus resulting from aqueduct stenosis caused papilloedema, which disappeared after treatment for hydrocephalus.
1 Indicates present; 2, absent; N, normal; A, abnormal; m, male.
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develop GHD (patients G and H), although patient H
developed this complication after the follow-up pe-
riod. In 1 other child (patient I), both GHD and CPP
developed after radiotherapy of the cranium for an
astrocytoma. These 3 children were not included in
this study.
DISCUSSION
The prevalence of GHD in children with NF1 was
2.5%, significantly higher than the 0.03% observed in
the general pediatric population.14 In 1 of the 3 chil-
dren with GHD, a chiasma glioma was detected; 1 of
the 9 (11.1%) children with a chiasma glioma pre-
sented with GHD. In our 3 cases, no growth of neu-
rofibromas that could be ascribed to GH therapy was
observed during clinical follow-up.
In our study, the prevalence of CPP is similar to
the 3% observed by Habiby et al6 (Table 2). In con-
trast, we did not find evidence that optic chiasm
glioma is a prerequisite for CPP, because only one of
three children with CPP had an optic chiasm glioma
at the time of diagnosis. This is the first observation
demonstrating that a chiasma glioma can be absent
in the presence of CPP, using MRI.
Strikingly, in our study, all endocrinologic disor-
ders were observed in boys. In the literature, CPP is
reported 8 times more often in girls than in boys and
is sporadic and idiopathic in most cases.15 However,
underlying organic disorders are more commonly
discovered in male patients. Habiby et al6 found a
female:male ratio of 2:5 in children with NF1 and
CPP, as opposed to a female:male ratio of 22:11 in
children with an optic pathway glioma.4 It appears
that being a male with NF1 somehow predisposes
one to CPP without an apparent explanation.
Saxena16 was the first to report precocious puberty
as well as marked growth retardation in children
with NF1. Various case reports published later on
endocrine manifestations in NF117–20 concerned pri-
marily CPP (Table 2), not GHD. Comparison of the
studies is difficult because of the lack of clinical data
as well as the fact that diagnostic criteria for NF1
were only defined by NIH in 1987. In addition, de-
tection of optic pathway glioma with neuroimaging
became more sensitive with the introduction of MRI.
Generally, it was thought that all endocrinologic dis-
orders in NF1 could be attributed to central nervous
system tumors, such as chiasmal optic gliomas, com-
promising hypothalamic and pituitary function.2,21 In
a study comparing the clinical manifestations and
natural history of optic pathway gliomas in children
with NF1 compared with children without NF1, List-
ernick et al22 reported CPP in 5 of 17 children with an
optic glioma and NF1, in contrast to no cases of CPP
in a group of children with an optic pathway glioma
and no features of NF1. The latter group appears
predisposed toward endocrinologic complications,
because chiasmal involvement was significantly
more common. This seems to suggest an association
between CPP and NF1 itself, which cannot be attrib-
uted solely to the presence of a chiasma glioma. Our
data support this association.
Possible causal mechanisms may be cerebral ab-
normalities still undetected at a neuroimaging level,
such as slow-growing hamartomas. In 2 patients
with CPP and 1 patient with GHD studied by T2-
weighted MRI of the brain, high-signal-intensity foci
were observed in the brainstem and supratentorial
regions of the brain. These white matter lesions are
common in children with NF1 and frequently in-
crease in size or number, later resolving as the chil-
dren get older.23 They are, however, not likely to be
correlated with the development of CPP or GHD,
because they are classically localized outside the
sellar and suprasellar regions of the brain. Another
possible explanation could be abnormalities at a cel-
lular level. The latter is supported by current evi-
dence that suggests that neurofibromin, the protein
encoded by the NF1 gene, is part of a signal trans-
duction chain extending from extracellular signals to
transcriptional regulation in the nucleus.24
As a university clinic, we may examine more se-
vere cases than generally seen in other hospitals.
However, all but one case presented during follow-
up. In contrast, the last child was referred with en-
larged testes and pubic hair at 8 years of age. The
high number of familial cases of NF1 observed in this
TABLE 2. Studies on Endocrine Manifestations of NF1
Author/Reference
(Year)
Neuroimaging Technique Number of
Children
Reason for Referral Results
Saxena/16 (1970) PEG 5 Growth/endocrine NF1, intracranial mass in 1/5 patients
X-ray skull disorders
Tertsch/17 (1979) PEG 1 Premature menstruation NF1, chiasma glioma
X-ray skull/optic foramina
Iraci/18 (1980) PEG 24 OPG 3/24 (12.5%) children OPG develop CPP
X-ray skull/optic foramina
Buonaguidi/19 (1982) PEG 4 CPP 1/4 NF1 and OPG
CT
Laue/20 (1985) CT 7 CPP 1 OPG 4/7 children had NF1
Habiby/6 (1995) MRI 219 NF1 7/219 (3%) CPP, all chiasma glioma
CT 7/18 (39%) patients with chiasma
glioma developed CPP
Cnossen et al (1997) MRI 122 NF1 3/122 (2.5%) CPP, 1/3 chiasma glioma
3/122 (2.5%) GHD, 1/3 chiasma glioma
2/9 (11%) patients with chiasma glioma
developed CPP or GHD
PEG indicates pneumoencephalogram; OPG, optic pathway glioma.
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group of children may be attributable to an ascer-
tainment bias, although approximately half of the
NF1 patients examined were familial cases and half
were sporadic cases. The disease was inherited from
both mothers and fathers.
In conclusion, CPP and GHD are important com-
plications in children with NF1. Although a glioma
of the optic chiasm is often encountered in these
patients, CPP and GHD also appear to develop in the
absence of an optic chiasm glioma. Diagnostic fol-
low-up is essential in children with NF1, because
premature manifestations of puberty and deviations
from the growth curve may be recognized. Subse-
quently, early treatment with LHRH analogues or
recombinant human GH, respectively, can be initi-
ated with possible attainment of target height. Con-
tinuous monitoring will also help to establish any
possible side effects of these interventions.
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